Gnanapavan S - Search Results

1

Alemtuzumab depletion failure can occur in multiple sclerosis.

Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S, Giovannoni G, Schmierer K. Dubuisson N, et al. Among authors: gnanapavan s. Immunology. 2018 Jun;154(2):253-260. doi: 10.1111/imm.12879. Epub 2018 Jan 4. Immunology. 2018. PMID: 29247512 Free PMC article.

2

Neural cell adhesion molecule--description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders.

Gnanapavan S, Grant D, Illes-Toth E, Lakdawala N, Keir G, Giovannoni G. Gnanapavan S, et al. J Neuroimmunol. 2010 Aug 25;225(1-2):118-22. doi: 10.1016/j.jneuroim.2010.04.020. Epub 2010 Jun 1. J Neuroimmunol. 2010. PMID: 20605643

3

Surviving stiff-person syndrome: a case report.

Gnanapavan S, Vincent A, Giovannoni G. Gnanapavan S, et al. J Neurol. 2011 Oct;258(10):1898-900. doi: 10.1007/s00415-011-6015-z. Epub 2011 Mar 26. J Neurol. 2011. PMID: 21442460

4

Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis.

Gnanapavan S, Grant D, Pryce G, Jackson S, Baker D, Giovannoni G. Gnanapavan S, et al. Autoimmunity. 2012 Jun;45(4):298-303. doi: 10.3109/08916934.2012.654865. Epub 2012 Feb 15. Autoimmunity. 2012. PMID: 22276904

5

Progression in multiple sclerosis is associated with low endogenous NCAM.

Gnanapavan S, Ho P, Heywood W, Jackson S, Grant D, Rantell K, Keir G, Mills K, Steinman L, Giovannoni G. Gnanapavan S, et al. J Neurochem. 2013 Jun;125(5):766-73. doi: 10.1111/jnc.12236. Epub 2013 Apr 19. J Neurochem. 2013. PMID: 23495921 Free PMC article.

6

Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression.

Gnanapavan S, Grant D, Morant S, Furby J, Hayton T, Teunissen CE, Leoni V, Marta M, Brenner R, Palace J, Miller DH, Kapoor R, Giovannoni G. Gnanapavan S, et al. PLoS One. 2013 Aug 1;8(8):e70019. doi: 10.1371/journal.pone.0070019. Print 2013. PLoS One. 2013. PMID: 23936370 Free PMC article.

7

Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.

Amor S, van der Star BJ, Bosca I, Raffel J, Gnanapavan S, Watchorn J, Kuhle J, Giovannoni G, Baker D, Malaspina A, Puentes F. Amor S, et al. Among authors: gnanapavan s. Mult Scler. 2014 Sep;20(10):1355-62. doi: 10.1177/1352458514521887. Epub 2014 Feb 10. Mult Scler. 2014. PMID: 24515731

8

A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann's syndrome.

Gnanapavan S, Jaunmuktane Z, Baruteau KP, Gnanasambandam S, Schmierer K. Gnanapavan S, et al. BMC Neurol. 2014 Apr 2;14:68. doi: 10.1186/1471-2377-14-68. BMC Neurol. 2014. PMID: 24694183 Free PMC article.

9

Growth associated protein (GAP-43): cloning and the development of a sensitive ELISA for neurological disorders.

Gnanapavan S, Yousaf N, Heywood W, Grant D, Mills K, Chernajovsky Y, Keir G, Giovannoni G. Gnanapavan S, et al. J Neuroimmunol. 2014 Nov 15;276(1-2):18-23. doi: 10.1016/j.jneuroim.2014.07.008. Epub 2014 Jul 23. J Neuroimmunol. 2014. PMID: 25175067

10

Developing Biomarkers for MS.

Gnanapavan S, Giovannoni G. Gnanapavan S, et al. Curr Top Behav Neurosci. 2015;26:179-94. doi: 10.1007/7854_2014_362. Curr Top Behav Neurosci. 2015. PMID: 25502545 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

68 results

Search Page